AGP Limited is proud to be recognized as one of the ‘Top Exporter’ at the 7th Pharma Export Summit & Awards 2024.

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > Glyziamet

Product List

Glyziamet

Generic:

Sitagliptin, Metformin
Therapeutic Class:

DPP-IV Inh & Biguanide Comb

Composition:

GlyziaMet contains 50 mg sitagliptin and either 500 mg metformin hydrochloride extended-release (50 mg/500 mg) or 1000 mg metformin hydrochloride extended-release (50 mg/1000 mg).

Description:

GlyziaMet tablets contain two oral antidiabetic medications used in the management of type 2 diabetes: Sitagliptin and Metformin hydrochloride.

Indications:

GlyziaMet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate.
Dosage:
The dose of GlyziaMet should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the healthcare provider. In patients not currently treated with metformin, the recommended total daily starting dose of GlyziaMet is 100 mg sitagliptin and 1000 mg metformin hydrochloride (HCl).

Presentation:

GlyziaMet (Sitagliptin/Metformin) Tab 50/500 mg and 50/1000 mg is available in pack of 14’s.